Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 7/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.35 |
| ▸ | MGAM | O43451 | 2/20 | 0.34 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | SI | P14410 | 2/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3406506 | 0.83 | NAMPT (0.39) | PTK2GRM2BACE1SLC9A1MGAM | |
| SCHEMBL251664 | 0.83 | PTK2 (0.40) | PTK2GRM2SLC9A1MGAMAMY1A | |
| SCHEMBL253221 | 0.78 | PIK3CG (0.36) | PTK2GRM2BACE1MGAMAMY1A | |
| Hydrochloric Acid SCHEMBL251752 | 0.77 | PIK3CG (0.35) | PTK2GRM2BACE1CDK9PABPC1 | |
| SCHEMBL31473638 | 0.72 | SLC9A1 (0.58) | PTK2GRM2SLC9A1MGAMAMY1A | |
| SCHEMBL20529652 | 0.72 | SLC9A1 (0.58) | PTK2GRM2SLC9A1MGAMAMY1A | |
| SCHEMBL18117053 | 0.72 | PTK2 (0.36) | PTK2GRM2SLC9A1MGAMAMY1A | |
| SCHEMBL16042826 | 0.71 | GRM2 (0.62) | PTK2GRM2SLC9A1 | |
| SCHEMBL31642496 | 0.70 | SLC9A1 (0.60) | GRM2SLC9A1MGAMAMY1AGAA | |
| SCHEMBL26978926 | 0.70 | KMO (0.42) | PTK2SLC9A1MGAMAMY1AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313407-B1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2016-10-05 | — | — | EP | disclosed |
| EP-2313407-B1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-20130315895-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-28 | — | — | US | disclosed |
| EP-2588107-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | Takeda Pharmaceutical Company Limited (JP) | 2013-05-08 | — | — | EP | disclosed |
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| WO-2012003338-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003338-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-05 | — | — | WO | disclosed |
| EP-2313407-A1 | cMET INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| WO-2010019899-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019899-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130315895-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | HGF, MET, HGFAC | PTK2 1122/4885GRM2 572/4885BACE1 1336/4885 |
| US-20100063054-A1 | cMET INHIBITORS | CEPT1, LCAT, GNMT | PTK2 2294/4885GRM2 2259/4885BACE1 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.